Runs a diversified set of businesses grouped under Manufacturing, Trading and Indenting, Property Development, and Others. Manufacturing is the most consistently profitable named segment, covering machine tools, vending, glass (Vitrum Glass Division), foods, and industrial equipment. Trading and Indenting is the largest named segment by revenue but ran thin on EBIT in FY26, while Property Development contributed a small slice of revenue and EBIT. The company also reports across Healthcare, Rental on leasehold land, and Others segments. FY26 total revenue was ₹731.20 crores with a net profit of ₹51.55 crores and an EBITDA margin of 14.33%. The largest cost line is other operating expenses at 27.9% of revenue, followed by employee costs at 18.6% and materials at 12.1%. A Medtech Division has been set up, with a Divisional CEO appointed in March 2026. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Manufacturing, Trading and Indenting, Property Development, Others. Diversified conglomerate with manufacturing, trading, property and an emerging medtech vertical.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 544 | 682 | 606 | 677 | 731 |
| EBITDA (ex other income) | 59 | 79 | 64 | 70 | 86 |
| margin % | 10.8 | 11.5 | 10.6 | 10.3 | 11.8 |
| Owners' profit | 24 | 36 | 37 | 34 | 52 |
| EPS, as reported (₹) | 39.49 | 59.21 | 61.67 | 57.42 | 85.91 |
| ROE % · ROCE % | 9.3 · 10.5 | 12.5 · 14.6 | 12.3 · 15.2 | 11.0 · 12.7 | 14.7 · 15.4 |
| Debt / equity (x) | 0.87 | 0.60 | 0.53 | 0.46 | 0.47 |
| Cash from operations | 53 | 79 | 75 | 92 | 59 |
| Capex | (10) | (7) | (12) | (7) | (14) |
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 152 | 163 | 176 | 186 | 167 | 180 | 189 | 195 |
| Profit before tax | 11 | 11 | 12 | 6 | 10 | 14 | 12 | 24 |
| Net profit | 10 | 10 | 11 | 4 | 10 | 12 | 11 | 19 |
| EPS (₹) | 16.14 | 16.35 | 17.53 | 7.40 | 16.04 | 20.65 | 17.64 | 31.59 |
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Manufacturing | 246 | 33.6 |
| Trading and Indenting | 351 | 48.0 |
| Property Development | 37 | 5.0 |
| Others | 98 | 13.4 |
| Total, before eliminations | 731 | 100.0 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| GODREJ INDUSTRIES LTD | 38,055 | 32.4 | 1.64 | 14.5 | 10.4 | 6.4 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 18 Aug 2026 · Annual Report FY 2025-26 weblink filed, 125th AGM on Sep 16, 2026 | compliance | low | — | — |
| 18 Aug 2026 · Empire Industries AGM Notice Published in Newspapers | compliance | minimal | — | — |
| 17 Aug 2026 · Empire Industries Q1 FY27 standalone results: PAT up 47% YoY at Rs 14.17 crore | compliance | minimal | — | — |
| 17 Aug 2026 · 125th AGM on Sept 16, 2026; Record Date Sept 9 for Final and Special Dividend | board shareholder meetings | low | — | — |
| 17 Aug 2026 · Empire Industries 125th AGM on Sep 16 2026, Annual Report FY 2025-26 | board shareholder meetings | medium | — | — |
| 14 Aug 2026 · Empire Industries Q1 FY27 PAT jumps 47% YoY to Rs 14.17 cr on Rs 183.6 cr revenue | results | high | — | — |
| 3 Aug 2026 · Board meeting on 14 Aug 2026 to consider Q1 FY27 results | results | low | — | — |
| 8 Jul 2026 · Routine filing - no share demat or remat activity in Q1 FY27 | compliance | minimal | — | — |
| 18 Jun 2026 · Trading Window Closure for Q1 FY27 Results | compliance | minimal | — | — |
| 10 Jun 2026 · Newspaper publications for transfer of shares to IEPF for FY 2018-2019 | compliance | minimal | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| 19.0 |
| 27.3 |
| 3M INDIA LIMITED | 36,735 | 60.1 | 17.11 | 42.6 | 27.2 | 35.7 | 6.8 | 21.7 |
| DCM SHRIRAM LIMITED | 15,675 | 10.8 | 2.03 | 10.9 | 11.1 | 9.5 | 11.4 | 11.7 |
| KAMA HOLDINGS LTD. | 7,275 | 7.8 | 0.48 | 1.9 | 12.3 | — | 13.5 | 22.4 |
| BALMER LAWRIE & CO LTD | 2,883 | 10.3 | 1.38 | 7.4 | 13.0 | 11.2 | 12.2 | 14.8 |
| TTK HEALTHCARE LIMITED | 1,576 | 21.3 | 1.41 | — | 5.9 | 7.4 | — | 12.2 |
| EMPIRE INDUSTRIES LTD. ◆ | 634 | 12.3 | 1.80 | — | 14.7 | 10.5 | — | 19.5 |
| GILLANDERS ARBUTHNOT LTD | 223 | 12.8 | 0.86 | 10.5 | 3.7 | 3.5 | 0.0 | 9.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 12.3 | 12.3 | 8 of 15 | 50% |
| P/B | 1.8 | 1.2 | 12 of 14 | 15% |
| ROCE | 10.5 | 8.4 | 5 of 14 | 69% |
| ROE | 14.7 | 10.7 | 4 of 14 | 77% |
| Debt / Equity | 0.5 | 0.3 | 10 of 14 | 31% |
| EBITDA margin | 19.5 | 20.6 | 8 of 14 | 46% |
| Revenue growth | 4.8 | 11.9 | 11 of 14 | 23% |
| Profit growth | 326.9 | 100.4 | 3 of 13 | 83% |
| Market cap | 634 | 223 | 7 of 15 | 57% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
